Canadian Cancer Trials Group Bulletins

General


Recent Publications

Canadian Cancer Trials Group BR.19: A Phase III Prospective Randomized Double Blind Placebo Controlled Trial of the Epidermal Growth Factor Receptor Antagonist ZD1839 (IRESSA) in Completely Resected Stage IB, II, and IIIA Non-Small Cell Lung Cancer

The purpose of the trial was to:
  • compare whether adjuvant treatment with ZD1839 (IRESSA) is superiour to placebo in patients with completely resected stage IB, II and IIIA non-small cell lung cancer in terms of : overall survival and disease-free survival; and,
  • confirm the prognostic significance and assess the predictive ability of EGFR expression, phosphorylation and mutations and the likelihood of "response" to ZD1839 (IRESSA) in terms of overall survival.

Although the trial was closed early (503 of 1242 planned patients were randomly assigned) and definitive statements regarding the efficacy of adjuvant gefitinib cannot be made, the results of the trial indicate that it is unlikely to be of benefit.

Goss GD, O'Callaghan C, Lorimer I, Tsao MS, Masters GA, Jett J, Edelman MJ, Lilenbaum R, Choy H, Khuri F, Pisters K, Gandara D, Kernstine K, Butts C, Noble J, Hensing TA, Rowland K, Schiller J, Ding K, Shepherd FA. Gefitinib Versus Placebo in Completely Resected Non-Small-Cell Lung Cancer: Results of the Canadian Cancer Trials Group BR19 Study. (ONLINE) J Clin Oncol 2013.

http://jco.ascopubs.org/content/early/2013/08/22/JCO.2013.51.1816.abstract

______________________________________

Canadian Cancer Trials Group BR.16 (ECOG 5597) -- Phase III Chemoprevention Trial of Selenium Supplementation in Persons With Resected Stage 1 Non-Small Cell Lung Cancer

The purpose of the trial was to evaluate the incidence of second primary tumors in patients with resected non-small-cell lung cancer receiving selenium supplementation. The authors conclude that selenium was safe but conferred no benefit over placebo in the prevention of second primary tumours in patients with resected NSCLC.

Karp DD, Lee SJ, Keller SM, Wright GS, Aisner S, Belinsky SA, Johnson DH, Johnston MR, Goodman G, Clamon G, Okawara G, Marks R, Frechette E, Caskill-Stevens W, Lippman SM, Ruckdeschel J, Khuri FR. Randomized, Double-Blind, Placebo-Controlled, Phase III Chemoprevention Trial of Selenium Supplementation in Patients With Resected Stage I Non-Small-Cell Lung Cancer: ECOG 5597 (ONLINE). J Clin Oncol 2013.

http://jco.ascopubs.org/content/early/2013/09/03/JCO.2013.49.2173.abstract